Back to Journals » Pediatric Health, Medicine and Therapeutics » Volume 3

Biologics for the treatment of moderate- to-severe ulcerative colitis in pediatric patients

Authors Albenberg LG, Mamula P, Kelsen

Received 2 May 2012

Accepted for publication 8 June 2012

Published 19 July 2012 Volume 2012:3 Pages 51—58


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Download Article [PDF] 

Lindsey G Albenberg, Petar Mamula, Judith R Kelsen
Division of Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, Philadelphia, PA, USA

Abstract: Ulcerative colitis (UC) is a chronic, inflammatory disease of the large intestine. In pediatric patients, UC is associated with significant morbidity including persistent symptoms affecting quality of life, hospitalizations, and surgery, and therapeutic strategies are limited. The advent of biologics, specifically anti-tumor necrosis factor- α medications, has been very beneficial for pediatric patients suffering from UC. Since the introduction of these therapies, there has been improvement in the rates of both remission as well as colectomy-free survival. However, there has been concern regarding the adverse events associated with these medications including the risk of infection and malignancy. The efficacy and safety of infliximab, the most frequently used biologic medication in pediatric patients with UC, will be the focus of this review.

Keywords: ulcerative colitis, biologics, anti-TNF-α, infliximab, adalimumab

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]